Cohorte Nationale VIH-2 (ANRS CO VIH2)

ANRS, Emerging Infectious Diseases

Status: Unknown

Conditions: HIV-2 Infection

Treatments: Drug: Antiretroviral

Study type: Observational

Funder types: Other

Identifiers

NCT04658329

ANRS CO5 VIH-2

Details and patient eligibility

About

The HIV2 study is an open cohort of prospective, multicentric, national observation. The main objective is to study HIV-2 infection in adult patients followed in France.

Full description

The secondary objectives are :

• Describe the epidemiological and clinical characteristics of participants infected with HIV-2, and the immuno-virological characteristics of the infection.
• To study the clinical and immunological progression of HIV-2 infection and the prognostic factors of this evolution.
• Study the response to antiretroviral treatment (clinical, immuno-virological) and contribute to the identification of the antiretroviral strategies and combinations most suited to the particularities of the infection.
• Allow an evaluation of the care practices of participants followed in French hospitals
• Provide a bank of clinical-biological data and samples allowing the performance of virological and / or immunological studies on HIV-2 infection.

The follow-up of the participants is different according to the therapeutic status of the participants, naive of antiretroviral treatment or already treated with antiretrovirals.

Enrollment: 1,185 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV-2 infection only, diagnosed by ELISA, confirmed by Western-Blot test,
• Follow-up in consultation or hospitalization in one of the investigating centers,
• Age greater than or equal to 18 years,
• Prolonged follow-up possible, residence in France planned for at least one year,
• Consent to participate,
• Long-term medical care possible for the participant, or by medical aid (AME), or declaration of obtaining AME at the time of inclusion.

Exclusion criteria

• HIV-1 infection
• Double HIV-1 + HIV-2 seropositivity